Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Haematopoietic Cell Transplantation: Extended Follow-Up of the Phase 2 Multi-Cohort CheckMate 205 Study

被引：0
|
作者：
Collins, G. [1 ]
Armand, P. [2 ]
Engert, A. [3 ]
Younes, A. [4 ]
Lee, H. J. [5 ]
Santoro, A. [6 ]
Zinzani, P. L. [7 ]
Timmerman, J. [8 ]
Ramchandren, R. [9 ]
Cohen, J. [10 ]
De Boer, J. P. [11 ]
Savage, K. [12 ]
Kuruvilla, J. [13 ,14 ]
Trneny, M. [15 ,16 ]
Shipp, M. [2 ]
Sacchi, M. [17 ]
Sumbul, A. [17 ]
Ansell, S. [18 ]
机构：
[1] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Hosp Cologne, Cologne, Germany
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Humanitas Univ, Humanitas Canc Ctr, Milan, Italy
[7] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy
[8] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA
[9] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[11] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[12] BC Canc, Vancouver, BC, Canada
[13] Univ Toronto, Vancouver, BC, Canada
[14] Princess Margaret Canc Ctr, Vancouver, BC, Canada
[15] Charles Univ Prague, Prague, Czech Republic
[16] Gen Univ Hosp Prague, Prague, Czech Republic
[17] Bristol Myers Squibb, Princeton, NJ USA
[18] Mayo Clin, Rochester, MN USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷
关键词：
checkpoint inhibitor; Hodgkin lymphoma; long-term outcomes; programmed death-1;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH19-PO-0
引用
收藏
页码：80 / 81
页数：2
相关论文
共 50 条
  • [41] The role of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma - a long-term follow-up single center experience
    Roerden, M.
    Soekler, M.
    Kanz, L.
    Bethge, W.
    Vogel, W.
    Walz, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 163 - 163
  • [42] 2-Year Follow-Up Results From the Phase 1-2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 10 - 11
  • [43] Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.
    Su, Hang
    Song, Yongping
    Jiang, Wenqi
    Sun, Xiuhua
    Qian, Wenbin
    Zhang, Wei
    Gao, Yuhuan
    Jin, Zhengming
    Zhou, Jianfeng
    Jin, Chuan
    Zou, Liqun
    Qiu, Lugui
    Li, Wei
    Yang, Jianmin
    Hou, Ming
    Zeng, Shan
    Liu, Peng
    Shi, Yuankai
    Zhou, Hui
    Wang, Shuyan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Long term follow-up after autologous stem cell transplantation for chemoresistent Hodgkin's lymphoma
    Pavone, V
    Gaudio, F
    Guarini, A
    Perrone, T
    Curci, P
    Giordano, A
    De Francesco, R
    Liso, V
    ANNALS OF ONCOLOGY, 2005, 16 : 198 - 198
  • [45] Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
    Younes, Anas
    Sureda, Anna
    Ben-Yehuda, Dina
    Zinzani, Pier Luigi
    Ong, Tee-Chuan
    Prince, H. Miles
    Harrison, Simon J.
    Kirschbaum, Mark
    Johnston, Patrick
    Gallagher, Jennifer
    Le Corre, Christophe
    Shen, Angela
    Engert, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2197 - 2203
  • [46] Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT
    Martinez, Carmen
    Boumendil, Ariane
    Romejko-Jarosinska, Joanna
    Anagnostopoulos, Achilles
    Faber, Edgar
    Poire, Xavier
    Yakoub-Agha, Ibrahim
    Akhtar, Saad
    Gurman, Gunhan
    Pavone, Vincenzo
    Halaburda, Kazimierz
    Sousa, Aida Botelho
    Ghesquieres, Herve
    Finel, Herve
    Khvedelidze, Irma
    Montoto, Silvia
    Sureda, Anna
    LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2915 - 2922
  • [47] Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
    Moskowitz, Alison J.
    Advani, Ranjana H.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Christian, Beth A.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Brown, Lisa
    Taft, David
    Ansari, Sahar
    Zak, Daniel E.
    Sacchi, Mariana
    Manley, Thomas
    Herrera, Alex F.
    BLOOD, 2019, 134
  • [48] Long-term Follow-Up After Autologous Haematopoietic Stem Cell Transplantation: The Italian Multiple Sclerosis Cohort
    Boffa, G.
    Sormani, M. P.
    Repice, A. M.
    Capobianco, M.
    Moiola, L.
    Amato, M. P.
    Cottone, S.
    Frau, J.
    Zimatore, G. B.
    Radaelli, M.
    Gasperini, C.
    Caniatti, L. M.
    Gualandi, F.
    Inglese, M.
    Uccelli, A.
    Massacesi, L.
    Saccardi, R.
    Mancardi, G. L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 198 - 199
  • [49] A Retrospective Study of 108 Cases of Relapsed or Refractory Classical Hodgkin Lymphoma: Second Line Therapies and Autologous Hematopoietic Stem Cell Transplantation
    Yang, Mingzi
    Wu, Meng
    Nuersulitan, Reyizha
    Liu, Yanfei
    Ping, Liya A. Lingyan
    Song, Yuqin
    Zhu, Jun
    BLOOD, 2018, 132
  • [50] Cost Effectiveness of Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL) after Failure of Autologous Stem Cell Transplantation (ASCT) and Treatment with Brentuximab Vedotin (BV) Treatment in Australia
    Tan, Marcus
    Lozano-Ortega, Greta
    Szabo, Shelagh
    Johnston, Karissa
    Connors, Joseph M.
    Chen, Clara
    Kim, Hansoo
    BLOOD, 2017, 130
12345